Richard Bonneau, Ph.D.

Vice President, Machine Learning Drug Discovery, Genentech, Inc.

Bonneau leads Prescient Design, a molecular design accelerator at Genentech (a member of the Roche Group) that pioneers new methods for combining machine learning and molecular modeling. Bonneau’s research spans multiple levels of biological structure learning and modeling biological networks to predicting and designing macromolecular and biomimetic structure. Rich received his Ph.D. at the University of Washington, Seattle, where he pioneered new methods to predict biomolecular structure as a member of the Rosetta project. At Genentech Research and Early Development (gRED), Bonneau and his team build new methods for applying machine learning to design, molecular composition, function and interfaces in ways that span all drug modalities.

Advancing Research in Basic Science and Mathematics Subscribe to our newsletters to receive news & updates